Two randomized vitamin D trials in ambulatory patients on anticonvulsants: Impact on bone

Neurology

Volumn 67, Issue 11, 2006, Pages 2005-2014

  Mikati, M A ^a   Dib, L ^a   Yamout, B ^a   Sawaya, R ^a   Rahi, A C ^a   Fuleihan, G El Hajj ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ERGOCALCIFEROL; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; VITAMIN D;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; BACKACHE; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTICONVULSANTS; BONE DENSITY; BONE DISEASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VITAMIN D;

EID: 33845707783     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000247107.54562.0e     Document Type: Article

References (30)

1. Ali II, Schuh, L, Barkley GL, Gates JR. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav 2004;5:296-300.
2. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786.
3. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353.
4. Mikati MA, Wakim RH, Fayad M. Symptomatic antiepileptic drug associated vitamin D deficiency in non-institutionalized patients; an underdiagnosed disorder. J Med Libanais 2003;51:71-73.
5. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
6. Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002;44:247-253 (erratum in Pediatr Int 2002;44:466).
7. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-638.
8. Fitzpatrick L. Pathophysiology of bone loss in patients receiving anticonvulsant therapy Epilepsy Behav 2004;5 (suppl 2):S3-S15.
9. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001;15:633-642.
10. Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 1973;4:695-701.
11. Hahn TJ, Halstead LR. Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration. Calcif Tissue Int 1979;27:13-18.
12. Pedrera JD, Canal ML, Carvajal J, et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000;30:895-899.
13. Silver J, Davies TJ, Kupersmitt E, Orme M, Petrie A, Vajda F. Prevalence and treatment of vitamin D deficiency in children on anticonvulsant drugs. Arch Dis Child 1974;49:344-350.
14. Tjellesen L, Gotfredsen A, Christiansen C. Effect of vitamin D2 and D3 on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 1983;68:424-428.
15. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716.
16. Arabi A, Baddoura R, Awada H, et al. Hypovitaminosis D osteopathy: is it mediated through PTH, lean mass, or is it a direct effect? Bone 2006;39:268-275.
17. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al. Effect of vitamin D replacement on musculoskeletal parameters in healthy school children: a randomized controlled trial. J Clin Endocrinol Metab 2006;91:405-412.
18. Chow L. Design and analysis of clinical trials, 2nd ed. New York: Wiley, 2004:142-143.
19. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine 1997. Available at http://www.nap.edu/books/0309063507/html/index.html. Accessed November 18, 2005.
20. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-294.
21. Salamoun MM, Kizirian A, Tannous R, et al. Low calcium and vitamin D intake in healthy children and adolescents and their correlates. Eur J Clin Nutr 2005;59:177-184.
22. Fleming KH, Heimbach JT. Consumption of calcium in the US: food sources and intake levels. J Nutr 1994;124:1426S-1430S.
23. Iuliano-Burns S, Whiting SJ, Faulkner RA, Bailey DA. Levels, sources, and seasonality of dietary calcium intake in children and adolescents enrolled in the university of Saskatchewan pediatric bone mineral accrual study. Nutr Res 1999;19:1471-1483.
24. El-Hajj Fuleihan G, Baddoura R, Awada H, Salam N, Salamoun M, Rizk P. Low peak bone mineral density in healthy Lebanese subjects. Bone 2002;31:520-528.
25. El-Hajj Fuleihan GE, Testa M, Angell J, Porrino N, LeBoff MS. Reproducibility of DXA densitometry: a model for bone loss estimates. J Bone Miner Res 1995;10:1004-1014.
26. Linde J. Hansen JM, Siersbaek-Nielsen K, Fuglsang-Frederiksen V. Vitamin D in patients on anticonvulsants. BMJ 1972;4:547.
27. Bachrach LK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: promises and pitfalls. J Pediatr Endocrinol Metab 2000;13:983-988.
28. Gidal BE, Elliott MB, Jones JC, Molina C. Treatment of hypovitaminosis D in patients receiving carbamazepine or phenytoin: biopharmaceutical considerations. Presented at the 2005 Meeting of the American Epilepsy Society.
29. Nashef L, Lamb E. Guidelines are needed for treating diseases of bone metabolism in epilepsy [letter]. BMJ 1999;318: 1285.
30. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5:S41-S47.